Nahuel Ezequiel Wanionok, María Silvina Molinuevo, Juan Manuel Fernandez, Lucas Nahuel Besada, Ana M Cortizo, Evelyn Castillo, Jessica Jirón, Claudia Sedlinsky, León Schurman, José Ignacio Aguirre, Antonio Desmond McCarthy
INTRODUCTION: We previously showed that a 3-week oral Metformin (MET) treatment enhances the osteogenic potential of bone marrow stromal cells (BMSCs) and improves several bone histomorphometric parameters in Wistar rats with metabolic syndrome (MetS). However, the skeletal effects of extended periods of MET are still not completely elucidated. Hence, we investigated the impact of a prolonged (3-month) MET treatment on bone architecture, histomorphometric and biomechanics variables and osteogenic potential of BMSCs in Wistar rats with or without MetS...
May 13, 2024: Experimental and Clinical Endocrinology & Diabetes